Rectal sparing approach after preoperative radio - and/or Chemo-therapy (ReSARCh): a prospective, multicentre, observational study
Gaya Spolverato,Quoc Riccardo Bao,Paolo Delrio,Mario Guerrieri,Monica Ortenzi,Nicola Cillara,Angelo Restivo,Simona Deidda,Antonino Spinelli,Carmela Romano,Francesco Bianco,Giacomo Sarzo,Emilio Morpurgo,Claudio Belluco,Elisa Palazzari,Giuditta Chiloiro,Elisa Meldolesi,Claudio Coco,Donato Paolo Pafundi,Cosimo Feleppa,Carlo Aschele,Michele Bonomo,Andrea Muratore,Alfredo Mellano,Germana Chiaulon,Filippo Crimì,Isacco Maretto,Alessandro Perin,Emanuele Damiano Luca Urso,Marco Scarpa,Mariasole Bigon,Federico Scognamiglio,Francesca Bergamo,Paola Del Bianco,Maria Antonietta Gambacorta,Daniela Rega,Salvatore Pucciarelli
DOI: https://doi.org/10.1097/js9.0000000000001322
2024-03-21
International Journal of Surgery
Abstract:Background: Rectal-sparing approaches for patients with rectal cancer who achieved a complete or major response following neoadjuvant therapy constitute a paradigm of a potential shift in the management of patients with rectal cancer, however their role remains controversial. The aim of this study was to investigate the feasibility of rectal-sparing approaches to preserve the rectum without impairing the outcomes. Methods: This prospective, multicentre, observational study investigated the outcomes of patients with clinical stage II-III mid-low rectal adenocarcinoma treated with any neoadjuvant therapy, and either transanal local excision or watch-and-wait approach, based on tumor response (major or complete) and patient/surgeon choice. The primary endpoint of the study was rectum preservation at a minimum follow-up of two years. Secondary endpoints were overall, disease-free, local and distant recurrence-free, and stoma-free survival at three years. Results: Of 178 patients enrolled in 16 centres, 112 (62.9%) were managed with local excision and 66 (37.1%) with watch-and-wait. At a median (interquartile range) follow-up of 36.1 (30.6-45.6) months, the rectum was preserved in 144 (80.9%) patients. The 3-year rectum-sparing, overall, disease-free, local recurrence-free, distant recurrence-free survival was 80.6% (95%CI 73.9-85.8), 97.6% (95%CI 93.6-99.1), 90.0% (95%CI 84.3-93.7), 94.7% (95%CI 90.1-97.2), and 94.6% (95%CI 89.9-97.2), respectively. The 3-year stoma-free survival was 95.0% (95%CI 89.5-97.6). The 3-year regrowth-free survival in the watch-and-wait group was 71.8% (95%CI 59.9-81.2). Conclusions: In rectal cancer patients with major or complete clinical response after neoadjuvant therapy, the rectum can be preserved in about 80% of cases, without compromise the outcomes.
surgery